Moses Ramos
Child & Adolescent Psychiatry · Desoto, TXNPI 1013137561
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $25.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Validus Pharmaceuticals LLC$1K
- AbbVie$833
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$648
- Supernus Pharmaceuticals, Inc.$566
- Otsuka America Pharmaceutical, Inc.$509
- Johnson & Johnson$488
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,342100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Validus Pharmaceuticals LLC | 15 | $1,246 |
| AbbVie(2 entities) | 40 | $833 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $648 |
| Supernus Pharmaceuticals, Inc. | 24 | $566 |
| Otsuka America Pharmaceutical, Inc. | 20 | $509 |
| Johnson & Johnson | 22 | $488 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $448 |
| Tris Pharma Inc | 15 | $410 |
| Lundbeck LLC | 19 | $378 |
| Corium, LLC | 14 | $377 |
| Neurocrine Biosciences, Inc. | 9 | $198 |
| Noven Therapeutics, LLC | 10 | $191 |
| Shire North American Group Inc | 11 | $181 |
| E.r. Squibb & Sons, L.L.C. | 8 | $174 |
| Alkermes, Inc. | 7 | $139 |
| Idorsia Pharmaceuticals US Inc | 6 | $98 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Vertical Pharmaceuticals, LLC | 4 | $70 |
| Adlon Therapeutics L.p. | 4 | $60 |
| Ironshore Pharmaceuticals Inc. | 3 | $55 |
| Neos Therapeutics, LP | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Equetro$919
- CAPLYTA$132
- Dyanavel XR$122
- Quillivant$122
- Quillichew ER$122
- REXULTI$119
How this compares
$7,350 in reported general payments places this provider in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $105,697 |
| Lisdexamfetamine Dimesylate | 12 | $2,123 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $1,533 |
| Aripiprazole | 38 | $1,425 |
| Duloxetine Hcl | 60 | $1,026 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 26 | $926 |
| Alprazolam | 131 | $808 |
| Bupropion Hcl SrBupropion Hcl | 55 | $772 |
| Eszopiclone | 21 | $455 |
| Fluoxetine Hcl | 59 | $450 |
| Bupropion XlBupropion Hcl | 22 | $447 |
| Buspirone Hcl | 20 | $429 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $395 |
| Lorazepam | 54 | $379 |
| Doxepin Hcl | 20 | $377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $198 | $105,69711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Other child & adolescent psychiatry in Desoto
- Alain KaticBellaire$106K
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- John SteffekSpring$14K
- Robert MosquedaEdinburg$13K
- Gloria BrunGreenville$10K
- Mudassar TariqSugar Land$9K
- Charles PryzantDallas$9K
- Mehvesh AfrinaPlano$8K
- Kishore SunkaraHurst$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.